From: Julius Wong | 3/21/2019 9:22:58 PM | | | | In an interview on CNBC, a Jefferies analyst said that Biogen ( BIIB -29.5%) may now be targeting acquisitions after its aducanumab flop. Attractive candidates include Biohaven Pharmaceutical Holding Company ( BHVN +8.2%), Neurocrine Biosciences ( NBIX +5.9%), Alder BioPharmaceuticals ( ALDR +6.2%), Sage Therapeutics ( SAGE +3.6%), ACADIA Pharmaceuticals ( ACAD +3.7%) and GW Pharmaceuticals ( GWPH +3.3%).
A Stifel analyst agreed, adding that Sarepta Therapeutics ( SRPT +2.1%) could be a target as well. |
| Munch-a-Biotech Today | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
To: Julius Wong who wrote (3148) | 3/21/2019 9:31:34 PM | From: tuck | | | Hmm. GWPH. Could also throw in Zogenix (ZGNX), it's undervalued (IMO) alter ego. With the IPR issue still hanging over BIIB's head, I'm in the incremental deals with smaller M&A targets camp.
Cheers, Tuck |
| Munch-a-Biotech Today | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |